2006
DOI: 10.1007/s10165-006-0461-y
|View full text |Cite
|
Sign up to set email alerts
|

Modeling and cost-effectiveness analysis of etanercept in adults with rheumatoid arthritis in Japan: a preliminary analysis

Abstract: The tumor necrosis factor (TNF) antagonist etanercept is an antirheumatic agent which was approved by Japanese regulatory authorities in January 2005. In Japan, the cost-effectiveness of this therapy for patients with rheumatoid arthritis (RA) has not previously been evaluated. This study models the cost-utility of etanercept in comparison with standard therapy with disease-modifying antirheumatic drugs (DMARDs) among adult Japanese RA patients who have failed a previous course of the DMARD bucillamine. A Mark… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
4
1

Citation Types

0
16
0

Year Published

2006
2006
2024
2024

Publication Types

Select...
4
1
1

Relationship

0
6

Authors

Journals

citations
Cited by 25 publications
(16 citation statements)
references
References 24 publications
0
16
0
Order By: Relevance
“…The 18 studies selected for inclusion were published inclusive of 2000–2007; 4 conducted CEAs (32–35) and 16 conducted CUAs (28, 34–48) (Tables 1 and 2). The number of comparisons within each study ranged from 1 to 20, comprising a total of 116 comparisons.…”
Section: Resultsmentioning
confidence: 99%
See 3 more Smart Citations
“…The 18 studies selected for inclusion were published inclusive of 2000–2007; 4 conducted CEAs (32–35) and 16 conducted CUAs (28, 34–48) (Tables 1 and 2). The number of comparisons within each study ranged from 1 to 20, comprising a total of 116 comparisons.…”
Section: Resultsmentioning
confidence: 99%
“…Biologics were compared to DMARD monotherapies (leflunomide [n = 1], methotrexate [n = 6], sulfasalazine [n = 1]) and combination therapies (cyclosporine + methotrexate [n = 1], hydroxychloroquine + sulfasalazine + methotrexate [n = 1]), DMARD sequences (n = 10), mixed drug treatments that included DMARDs and other drugs (e.g., NSAIDs; n = 1), and methotrexate + placebo (n = 1) (Table 1). Biologic treatment duration included 6 months (32, 33), 1 year (34, 42, 43), 2 years (44), and depending on response and toxicity, up to 5 years (44, 48), 10 years (44, 45), or the patient's lifetime (28, 35–41, 46, 47).…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…Sixteen cost-utility studies were involved (Bansback et al, [2011]), (Barbieri et al, [2011]), (Barton et al, [2004]), (Brennan et al, [2007]), (Chen et al, [2006]), (Coyle et al, [2006]), (Jobanputra et al,[2002]), (Kobelt et al, [2004]), (Kobelt et al, [2003]), (Kobelt et al, [2005]), Marra et al, [2007]), (Spalding and Hay, [2006]), (Tanno et al, [2006]), (Welsing et al, [2004]), (Wong et al, [2002]).…”
Section: Iii221 Systematic Review By Velde El Al (2011)mentioning
confidence: 99%